Pharmaceutical - Respiratory and Pulmonary, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Boehringer Ingelheim acquires Funxional products

24-07-2012

German family-controlled drug major Boehringer Ingelheim has entered an agreement to acquire the global…

Anti-Arthritics/RheumaticsBoehringer IngelheimFunxional TherapeuticsFX125LLicensingPharmaceuticalRespiratory and Pulmonarysomatotaxin

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017

06-11-2011

The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

Back to top